Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 July 2021 | Story Nonsindiso Qwabe | Photo Nonsindiso Qwabe
On top of the Drakensberg. The ARU and Witsieshoek Mountain Lodge research team are, from the left: Grant Martin, Dr Ralph Clark, Jan van Niekerk, Prof Aliza le Roux, Prof Peter Taylor, and Dr Sandy Steenhuisen.

All mountains around the world have native and non-native species that are expanding their ranges quite dramatically; however, little research has been conducted towards understanding the long-term redistribution of species and the effects of global change on biodiversity.


The Afromontane Research Unit (ARU) on the University of the Free State Qwaqwa Campus – as part of the Mountain Invasion Research Network – has secured a two-year EU Horizon 2020 project under the Department of Science and Innovation, which will be looking at the mechanisms underlying the success and impact of range-expanding species on biodiversity and ecosystem functioning.

On Monday 19 July 2021, the ARU took a few of its researchers on a scenic helicopter ride to the summit of the Drakensberg for an alpine field-experiment site inspection of the Mont-aux-Sources peak, one of the highest sections of the Drakensberg range. This site has been identified for the project which the research unit will be leading on mountain research.

ARU Director, Dr Ralph Clark, said the project would explore the effects of global change, biological invasions (when species invade new geographic regions), as well as climate and land-use change. He said experiments were needed to explore the various possibilities and to test the extent to which species respond to experimental treatments. The project would therefore be conducting experiments for two years using open-top chambers – causing an increase in temperature of 3 or 4 degrees to what you find naturally – on plant species from lower down to the top of the mountain, to see how they function. “This will give us an idea of whether they will be able to survive in global warming scenarios. If temperatures get warmer, we might start seeing a lot of plants up here that we wouldn’t otherwise find here.”

Dr Clark said little is known about the long-term monitoring of species distribution and the effects of global change. Implementing the project in the Maloti-Drakensberg alpine area will therefore put the area in the global mountain research arena. The elevational gradient in the Maloti-Drakensberg Mountains provides space to explore the key processes underlying the variation in species elevation with climate change. “One of the things we don’t know much about are alpine systems. We are hoping to establish a long-term alpine research site and try to add as many studies as we can. The more science we can bring up here, the more we can know about mountain life. What happens on mountains has a lot of impact on social dynamics.

“This project is looking to see what is driving range expansion. Every mountain has its own context. In the Swiss alpine, fires are not a big factor, but fires are one of the biggest factors on our mountains. Some of our native and non-native species are therefore fire-driven, so as fire increases, you might have them spreading faster.”

Listen to the article:

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept